Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Vedanta Biosciences has teamed with NYU Langone Medical Center to develop microbiome-derived immunotherapies for cancer patients receiving checkpoint inhibitors. The partners hope to understand how the gut microbiome affects the efficacy of checkpoint inhibitors and potentially develop drugs to modulate that interaction. In a separate microbiome-related pact, Johnson & Johnson will explore skin disease treatments with Xycrobe Therapeutics. Xycrobe has developed a library of “good” skin bacteria engineered to secrete therapeutics.
This article has been sent to the following recipient: